Author of

• 18374

  +

  P3.02b - Poster Session with Presenters Present (ID 494)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 18486

    +

    P3.02b-112 - Feasibility of Re-Biopsy in Patients with Non-Small Cell Lung Cancer after Failure of Epidermal Growth Factor Receptor Targeted Therapy (ID 5557)

    14:30 - 14:30  |  Author(s): J. Jang
    • Abstract
    • Slides

    Background:
    After failure of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), re-biopsy may be helpful to understand resistance mechanism and guide further treatment decision. However, re-biopsy is still challenging due to several hurdles, such as tissue availability, procedural feasibility, and limited new drugs. The aim of this study was to assess the feasibility of re-biopsy in advanced non-small cell lung cancer (NSCLC) in a real-practice.
    
    Methods:
    We retrospectively reviewed the clinical and pathologic data of advanced NSCLC patients who had disease progression after previous EGFR-TKI at single institution between January 2015 and February 2016.
    
    Results:
    Ninety-one patients had disease progression after using EGFR-TKI. Among them, thirty-three patients (36.3%) underwent re-biopsy. re-biopsy was successfully completed for thirty-two patients (97.0%) and only one patient didn’t get malignant cell. Three patients (9.1%) experienced a pneumothorax, however only one patient required closed thoracostomy. After re-biopsy, 27 patients were performed EGFR mutation test. Among 21 patients who had active mutation, the initial mutation was again found in 9 cases (42.9%) while the T790M mutation was found in 6 cases (28.6%). In 4 cases the initial EGFR mutation was no longer found. The patients who had re-biopsy were younger (61.2±9.7 vs. 66.1±10.8 years, p=0.03) and longer response duration (429±383 vs. 265±284 days, p=0.022) than the patients who didn’t.
    
    Conclusion:
    Re-biopsy in advanced NSCLC is feasible in the real practice especially in younger patient and patients with longer response duration of EGFR-TKI.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.